AMLX vs. ABCL, REPL, COLL, RCKT, EOLS, PHVS, AVBP, COGT, OCS, and BCYC
Should you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), Pharvaris (PHVS), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry.
Amylyx Pharmaceuticals vs.
Amylyx Pharmaceuticals (NASDAQ:AMLX) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
Amylyx Pharmaceuticals has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 28.0% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Amylyx Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat Amylyx Pharmaceuticals' return on equity.
AbCellera Biologics received 21 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 76.06% of users gave AbCellera Biologics an outperform vote while only 66.00% of users gave Amylyx Pharmaceuticals an outperform vote.
Amylyx Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, AbCellera Biologics had 9 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for AbCellera Biologics and 1 mentions for Amylyx Pharmaceuticals. AbCellera Biologics' average media sentiment score of 0.58 beat Amylyx Pharmaceuticals' score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.
Amylyx Pharmaceuticals presently has a consensus target price of $7.33, indicating a potential upside of 122.22%. AbCellera Biologics has a consensus target price of $8.00, indicating a potential upside of 164.03%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Amylyx Pharmaceuticals.
Summary
AbCellera Biologics beats Amylyx Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get Amylyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amylyx Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMLX) was last updated on 2/22/2025 by MarketBeat.com Staff
